Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

U.S. regulators approved the first GLP-1 weight-loss pill—a tablet formulation of Novo Nordisk’s NOVO.B5.00%increase; green up pointing triangle Ozempic and Wegovy—ushering in a new era of the obesity ...

Novo Nordisk NOVO.B1.08%increase; green up pointing triangle filed for U.S. Food and Drug Administration approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.

Every chief executive dreams of it: a product so successful that it propels their company from obscurity to superstardom seemingly overnight. Among the lessons from 2025, however, is that runaway ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.

Novo Nordisk NVO received Food and Drug Administration approval for its Wegovy pill as a treatment for obesity on Dec. 22. The company plans to launch the 25mg semaglutide pill in the United States in ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...

The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Wegovy pill, as it’s called, is first oral version of a GLP-1 drug that ...

The US Food and Drug Administration today approved a pill version of the blockbuster anti-obesity drug Wegovy. Made by Novo Nordisk, the pill is taken once a day. The company’s original version of ...

The pole position in the GLP-1 weight loss space is currently held by Eli Lilly. Novo Nordisk was the early leader, showing that being first doesn't always mean you stay at the head of the pack.